$BFLY

Executive Waves Goodbye to Nearly 14,000 Shares, Valued at More Than $100,000

Butterfly Network's (BFLY) CAO, Megan Carlson, sold 13,804 shares for over $100,000 to cover tax withholding. She retains 412,000 shares. BFLY's stock rose 381% in the past year, with a $2.1B market cap and $112.1M TTM revenue, but has a -40% return since 2021.

Original reporting
Published Sep 15, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Executive Waves Goodbye to Nearly 14,000 Shares, Valued at More Than $100,000 — source image
Decision brief

The 30-second read

$BFLYBearishLow
01

Why it matters

The Form 4 filing provides the first public disclosure of this insider transaction, offering a data point for investors monitoring insider activity.

02

Market read

Routine insider sell‑to‑cover; limited short‑term price impact but useful for compliance and monitoring of insider behavior.

03

What to watch

The sale occurs after a substantial price appreciation, which could attract profit‑taking by other insiders or large shareholders.

Relevance 4/10Novelty 3/10Timing: Sept 4 2026 (same‑day filing)

Background

Butterfly Network (BFLY) is a digital‑health medical‑device company with a market cap of $2.1 B and recent revenue growth.

Company-level read

Ticker impact

$BFLYBearishMedium confidence
Context

CAO Megan Carlson sold 13,804 shares of Class A common stock at $7.30 per share on Sept 4, 2026 (SEC Form 4 filing).

Expected impact

Potential slight dip in BFLY price, likely limited to a few basis points.

Evidence & confidence

The sale size (~$100k) is small relative to market cap ($2.1B) and follows a routine sell‑to‑cover policy, so impact is expected to be modest.

Market effects

Minimal effect on the medical‑device sector; insider sales are routine and not indicative of broader industry trends.

No discernible impact on regional markets.

Limited to investors tracking BFLY; no global market relevance.

Counterpoint

Given the strong 381% 12‑month return, the sale may be purely tax‑related and not a bearish signal.

Key entities

  • Megan Carlson

    Chief Accounting Officer and Senior Vice President, Finance of Butterfly Network.

  • Butterfly Network, Inc.

    Developer of portable ultrasound imaging devices.

Related articles

$QSIMed

2 Brain-Computer Interface Stocks to Watch While Neuralink Stays Private

Neuralink, a private brain-computer interface (BCI) company, successfully helped a patient with ALS communicate. Investors cannot buy Neuralink, but two public companies, Quantum-Si (QSI) and Butterfly Network (BFLY), are connected to the BCI field. QSI makes research tools and saw a 7x volume spike, while BFLY supplies ultrasound chips to BCI developers like Merge Labs and Bridge Neurotech.

$BFLYHigh

Why is Butterfly Network stock climbing today?

Butterfly Network (BFLY) stock rose 1.6% pre-market after Canaccord Genuity initiated coverage with a Buy rating and $10 target, citing its ultrasound tech and AI capabilities. Analysts highlight new products and partnerships. The stock has seen positive analyst activity, with a consensus target of $11.40. Q3 earnings are due October 29.

$BFLYHigh

Evercore ISI initiates Butterfly Network stock with outperform rating

Evercore ISI initiated coverage on Butterfly Network (NYSE: BFLY) with an outperform rating and $15.00 price target, citing its ultrasound-on-chip technology and growth potential. The firm projects $550M+ revenue by 2030 and positive EBITDA by 2028. BFLY stock has risen 367% over the past year, trading at $9.15 with a $2.44B market cap. Q2 2026 results showed a smaller loss than expected but lower revenue. Needham also initiated coverage with a buy rating and $10.00 target.

$BFLYHighAI 8/10

Why is Butterfly Network stock surging today?

Butterfly Network (BFLY) stock rose 11.5% after Needham initiated coverage with a Buy rating and $10 target, citing its ultrasound tech and Embedded business model. TD Cowen also has a Buy rating and $10 target. BFLY's Q3 revenue grew 39% YoY, with Embedded segment growth and expanding margins. The broader market had minimal impact on BFLY's surge.

$BFLYMed

Butterfly Network at Morgan Stanley conference: platform push widens reach

Butterfly Network (BFLY) presented its strategy at Morgan Stanley's conference, shifting from handheld ultrasound to a semiconductor imaging platform. The company reported 20% revenue growth, with $112M in last 12-month revenue, and highlighted partnerships like Midjourney. It aims to expand its addressable market to $250B through its Butterfly Embedded model. The company expects a fourth-generation chip in 2027 to improve image quality and challenge competitors. Management emphasized its strong

$BFLYMed

Butterfly Network (BFLY) Is Up 24.2% After Raising 2026 Guidance And Narrowing Losses - Has The Bull Case Changed?

Butterfly Network (BFLY) shares rose 24.2% after the company reported Q2 2026 revenue of $32.61M and a reduced net loss of $12.91M, and raised 2026 revenue guidance to $119M to $123M. The article cites improving losses and momentum in Embedded partnerships and enterprise point-of-care ultrasound, while noting ongoing cash burn and potential dilution risks.